In the updated WHO CNS5, more molecular markers were included, with three genetic features (TERTp mutation, EGFR gene amplification, [+7/−10] combined gain of entire chromosome 7 and loss of chromosome 10) becoming the criteria for diagnosing IDH‐wt GBM [4, 5]. This evidence concerns the gene IDH2 and glioblastoma.